Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to -$71000.0.

  • Barinthus Biotherapeutics' Deferred Taxes fell 226666.67% to -$71000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$115000.0, marking a year-over-year increase of 8675.12%. This contributed to the annual value of -$44000.0 for FY2024, which is 9856.91% up from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Deferred Taxes stood at -$71000.0 for Q3 2025, which was down 226666.67% from -$25000.0 recorded in Q2 2025.
  • Barinthus Biotherapeutics' Deferred Taxes' 5-year high stood at $3000.0 during Q4 2024, with a 5-year trough of -$1.9 million in Q4 2022.
  • For the 5-year period, Barinthus Biotherapeutics' Deferred Taxes averaged around -$404894.7, with its median value being -$57000.0 (2021).
  • In the last 5 years, Barinthus Biotherapeutics' Deferred Taxes plummeted by 1297142.86% in 2022 and then skyrocketed by 10036.54% in 2024.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Deferred Taxes stood at -$57000.0 in 2021, then plummeted by 3292.98% to -$1.9 million in 2022, then surged by 57.55% to -$821000.0 in 2023, then soared by 100.37% to $3000.0 in 2024, then tumbled by 2466.67% to -$71000.0 in 2025.
  • Its last three reported values are -$71000.0 in Q3 2025, -$25000.0 for Q2 2025, and -$22000.0 during Q1 2025.